Clik here to view.
BostonGeneと北海道大学病院がHER2陽性乳癌における新規診断技術開発で提携
WALTHAM, Mass. （ビジネスワイヤ） — 本日、BostonGene（本社：米国ボストン）は北海道大学病院との間で HER2 陽性乳癌患者を対象とした革新的診断技術の開発を推進することで合意しました。...
View ArticleClik here to view.
Otsuka and Astex announce that the European Commission has approved INAQOVI®...
LONDON & PLEASANTON, Calif. Otsuka Pharmaceutical Europe Ltd. (Otsuka) and Astex Pharmaceuticals, Inc. (Astex) today announce that the European Commission (EC) has approved INAQOVI® (oral...
View ArticleClik here to view.
BeiGene Strengthens Global Portfolio and Regains Full Rights from Novartis...
BASEL, Switzerland & BEIJING & CAMBRIDGE, Mass. BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, today announced that it has entered into an agreement...
View ArticleClik here to view.
BeiGene Announces Positive Regulatory Updates in Europe and the U.S. After...
BASEL, Switzerland & BEIJING & CAMBRIDGE, Mass. BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, today announced that the European Commission (EC) has...
View ArticleClik here to view.
血癌：AOP Health宣布在医学期刊《白血病》上发表针对真性红细胞增多症患者的最新研究结果
维也纳 (美国商业资讯)– AOP Orphan Pharmaceuticals GmbH (AOP Health)宣布在著名杂志《白血病》(Leukemia)上发表了最近开发的干扰素疗法ropeginterferon...
View ArticleClik here to view.
BostonGene and Hokkaido University Hospital Collaborate to Develop Novel HER2...
WALTHAM, Mass. BostonGene today announced an agreement with Hokkaido University Hospital to drive the discovery, validation and implementation of a groundbreaking stratification protocol for...
View ArticleClik here to view.
M.T.3’s LAVURCHIN® Receives Japanese Pharmaceutical Regulatory Approval as a...
TOKYO Malignant Tumor Treatment Technologies, Inc. (Headquarters: Tokyo; President and CEO: Toshiyasu Miyazaki; “M.T.3”) announced today that the Japanese pharmaceutical regulatory agency, the...
View ArticleClik here to view.
血液癌：AOPヘルス、医学雑誌「Leukemia」にて真性多血症患者における新たな知見を発表
ウィーン （ビジネスワイヤ） — AOP Orphan Pharmaceuticals...
View ArticleClik here to view.
Julie Gerardi加入Parse Biosciences，担任业务发展副总裁
西雅图 (美国商业资讯)– 业界领先的可访问和可扩展单细胞测序解决方案提供商Parse Biosciences今天宣布，Julie Gerardi已加入该公司，担任业务发展副总裁。Gerardi将会领导Parse的Evercode Whole Transcriptome、Evercode TCR和CRISPR Detect平台在药物研发业务中大规模应用方面的商业战略。...
View ArticleClik here to view.
BostonGeneは第82回日本癌学会学術総会にて、プレシジョン・メディシンに対する包括的アプローチを発表します。
WALTHAM, Mass. （ビジネスワイヤ） —...
View ArticleClik here to view.
EpimAb Biotherapeutics to Present Initial First-in-human Data of EMB-02 at...
SHANGHAI, China EpimAb Biotherapeutics, a clinical stage biotechnology company specializing in the development of bispecific antibodies, is pleased to announce that the company will present the...
View ArticleClik here to view.
BostonGene to Showcase Integrated Approach to Precision Medicine at the 82nd...
WALTHAM, Mass. BostonGene, a leading provider of AI-based molecular and immune profiling solutions, announced today that it will participate in the 82nd Annual Meeting of the Japanese Cancer...
View ArticleClik here to view.
ジュリー・ジェラルディ、パース・バイオサイエンシズの事業開発担当バイスプレジデントに就任
シアトル （ビジネスワイヤ） — アクセス性と拡張性に優れたシングルセル・シーケンシング・ソリューションの代表的企業であるパース・バイオサイエンシズは、ジュリー・ジェラルディが事業開発担当バイスプレジデントとして入社したことをお知らせいたします。同氏は創薬・開発における「Evercode Whole Transcriptome」「Evercode TCR」「CRISPR...
View ArticleClik here to view.
Kyowa Kirin Demonstrates Commitment to Real-world Evidence for POTELIGEO®...
TOKYO Kyowa Kirin International (KKI), a wholly owned subsidiary of Kyowa Kirin Co. Ltd, today announced the acceptance of an extensive programme of data to the annual meeting of the European...
View ArticleClik here to view.
Datopotamab Deruxtecan Demonstrated Statistically Significant and Clinically...
TOKYO & MUNICH & BASKING RIDGE, N.J. Positive topline results from the TROPION-Breast01 phase 3 trial showed datopotamab deruxtecan (Dato-DXd) demonstrated a statistically significant and...
View ArticleClik here to view.
PADCEV® (enfortumab vedotin-ejfv) and KEYTRUDA® (pembrolizumab) Significantly...
BOTHELL, Wash. & TOKYO Seagen Inc. (Nasdaq: SGEN) and Astellas Pharma Inc. (TSE:4503) today announced positive topline results from the Phase 3 EV-302 clinical trial (also known as KEYNOTE-A39)...
View ArticleClik here to view.
EPKINLY™ (epcoritamab) Approved by Japan Ministry of Health, Labour and...
COPENHAGEN, Denmark Genmab A/S (Nasdaq: GMAB) announced today that the Japan Ministry of Health, Labour and Welfare has approved EPKINLY™ (epcoritamab) as the first and only T-cell engaging...
View ArticleClik here to view.
デビオファーム、第82回「JCA-Mauvernay Award」授賞式において日本の先進的な癌研究を表彰
ローザンヌ・スイス （ビジネスワイヤ） — （ビジネスワイヤ） — スイスを拠点とするバイオ医薬品企業であるデビオファーム（www.debiopharm.com）は、2023 年日本癌学会学術賞「JCA-Mauvernay Award」の受賞者2名を発表しました。この名誉ある賞は、2つのカテゴリーにおいて日本における優れた癌研究を表彰するもので、画期的・革新的研究（Innovative...
View ArticleClik here to view.
Debiopharm Recognizes Pioneering Japanese Cancer Research During the 82nd...
LAUSANNE, Switzerland Debiopharm (www.debiopharm.com), a Swiss-based biopharmaceutical company, today announced the acknowledgement of the two recipients of the 2023 JCA-Mauvernay Award. This...
View ArticleClik here to view.
Elpiscience Announces First Patient Dosed for Phase 1 Clinical Trial of...
SHANGHAI & SUZHOU, China & GERMANTOWN, Md. Elpiscience Biopharmaceuticals (“Elpiscience”), a clinical-stage biopharmaceutical company dedicated to discovering and developing next-generation...
View Article